Stoke Therapeutics (NASDAQ:STOK) Director Sells $31,745.48 in Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) Director Edward Md Kaye sold 1,066 shares of the business’s stock in a transaction on Tuesday, December 2nd. The shares were sold at an average price of $29.78, for a total transaction of $31,745.48. Following the completion of the sale, the director owned 52,375 shares in the company, valued at $1,559,727.50. This represents a 1.99% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Stoke Therapeutics Trading Up 3.9%

STOK stock traded up $1.15 during trading on Wednesday, hitting $30.96. 665,349 shares of the stock traded hands, compared to its average volume of 1,025,254. Stoke Therapeutics, Inc. has a one year low of $5.35 and a one year high of $38.69. The stock has a market cap of $1.77 billion, a price-to-earnings ratio of 46.21 and a beta of 1.14. The company has a 50 day simple moving average of $28.74 and a 200 day simple moving average of $19.61.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.54) by ($0.11). The firm had revenue of $10.63 million for the quarter, compared to the consensus estimate of $6.06 million. Stoke Therapeutics had a return on equity of 13.28% and a net margin of 19.73%. As a group, analysts predict that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Stoke Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Generali Investments Management Co LLC bought a new position in Stoke Therapeutics in the third quarter valued at about $41,000. BNP Paribas Financial Markets lifted its position in Stoke Therapeutics by 66.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock valued at $48,000 after purchasing an additional 1,668 shares during the period. Tower Research Capital LLC TRC lifted its position in Stoke Therapeutics by 461.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock valued at $50,000 after purchasing an additional 3,591 shares during the period. AlphaQuest LLC bought a new position in shares of Stoke Therapeutics in the 1st quarter valued at about $72,000. Finally, US Bancorp DE grew its position in shares of Stoke Therapeutics by 9,743.9% during the 1st quarter. US Bancorp DE now owns 11,222 shares of the company’s stock worth $75,000 after buying an additional 11,108 shares during the period.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on STOK. Wedbush raised their price target on Stoke Therapeutics from $22.00 to $32.00 and gave the company an “outperform” rating in a report on Wednesday, November 5th. Needham & Company LLC increased their target price on Stoke Therapeutics from $22.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, October 10th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Stoke Therapeutics in a report on Monday. BTIG Research reiterated a “buy” rating and set a $39.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, November 5th. Finally, Canaccord Genuity Group increased their price objective on shares of Stoke Therapeutics from $24.00 to $28.00 and gave the stock a “buy” rating in a report on Wednesday, November 5th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $31.00.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.